24 results
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
reputation, business, results of operations, financial condition and prospects.
TNT119 may cause adverse events and/or undesirable side effects or have … penalties;
Tenet may be subject to litigation or product liability claims; and
Tenet’s reputation may suffer.
Any of these events could prevent Tenet
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
in (or would reasonably be expected to result in) material harm to the business or reputation of the Company; (iii) your material violation of any contract … engagement in conduct that results in (or would reasonably be expected to result in) material harm to the business or reputation of the Company
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
be harmed, which could significantly harm Tenet’s reputation, business, results of operations, financial condition and prospects.
TNT119 may cause adverse … other administrative, civil and criminal penalties;
Tenet may be subject to litigation or product liability claims; and
Tenet’s reputation may suffer
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
approval for, and commercialize TNT119 may be harmed, which could significantly harm Tenet’s reputation, business, results of operations, financial … liability claims; and
Tenet’s reputation may suffer.
Any of these events could prevent Tenet from achieving or maintaining market acceptance
10-K
c2bp 1hczlocs0w
7 Mar 22
Annual report
4:03pm
10-Q
ehy84
13 Sep 21
Quarterly report
4:01pm
424B4
hge15up92
11 Aug 21
Prospectus supplement with pricing info
5:05pm
S-1/A
l3rxxw0st i6
2 Aug 21
IPO registration (amended)
6:08am